AMINA OSMAN: Open Payments
NPI 1952725152 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$632 in 24 payments from 7 companies in 2025. Trend: 2023 $72 · 2024 $184 · 2025 $632
Food & beverage: $632
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $194 |
| E.R. Squibb & Sons, L.L.C. | 5 | $114 |
| Alkermes, Inc. | 6 | $108 |
| Neurocrine BioSciences, Inc. | 3 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| ABBVIE INC. | 2 | $43 |
| Janssen Pharmaceuticals, Inc | 1 | $34 |
Products named: UZEDY, COBENFY, ARISTADA, INGREZZA, REXULTI, VRAYLAR, INVEGA SUSTENNA.
Industry payments across DC — which companies pay providers there.
